Taselisib, a selective inhibitor of mutant PI3K, and ipatasertib, a selective ATP-competitive pan-Akt inhibitor, have been studied in clinical trials in combination with endocrine agents (NCT02340221, NCT02273973, NCT01296555) or taxanes (NCT02301988, NCT01862081, NCT02162719, NCT03337724), showing conflicting results in patients harboring PI3K/AKT/PTEN-altered tumours [14–18]. Here, AKT1 is linked to neoplasm.